RecruitingPHASE1, PHASE2NCT07182227
PS-002 for the Treatment of IgA Nephropathy in Adults
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Purespring Therapeutics Limited
- Intervention
- PS-002(genetic)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (11)
- University of Miami Hospital, Miami, Florida, United States
- The Johns Hopkins Hospital, Baltimore, Maryland, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Leicester General Hospital, Leicester, Leicestershire, United Kingdom
- Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
- Southmead Hospital, Bristol, United Kingdom
- Cardiff and Vale University Health Board, Cardiff, United Kingdom
- Royal Infirmary of Edinburgh Clinical Research Facility, Edinburgh, United Kingdom
- The Royal London Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07182227 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital
- RECRUITINGPHASE3NCT06963827A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney ConditionTakeda